Industry News
Biotechnology Industry News
Ever since 6-year-old Emily…
Ever since 6-year-old Emily Whitehead became the first patient to receive CAR-T cell therapy in 2012, where T cells were removed from her body and reprogrammed to attack her leukemia before being reinfused, drug developers
Takeda and Iambic Therapeutics…
Takeda and Iambic Therapeutics have agreed to a multiyear technology and discovery agreement that'll leverage Iambic’s broad suite of AI-driven drug discovery platforms. The agreement gives Iambic the chance to earn up to $1.7 billion.
ILiAD Biotechnologies Inc….
ILiAD Biotechnologies Inc. announced the close of an oversubscribed $115 million series B fund raise this week to support the company’s next generation pertussis (whooping cough) vaccine candidate.
On top of 348 known job cuts…
On top of 348 known job cuts across the organization last year, Genentech laid off an additional 141 staffers last August that are just now being disclosed.
The deal allows CSL to potentially…
The deal allows CSL to potentially exercise an option on recombinant polyclonal immunoglobulin products that could grant Memo up to $328 million on sales milestones.
Two dose-limiting toxicities have…
Two dose-limiting toxicities have been recorded in uniQure’s trial evaluating an investigational AAV gene therapy designed to treat the rare condition Fabry disease.
Belgian biotech Agomab…
Belgian biotech Agomab Therapeutics and eye-focused drug delivery company SpyGlass Pharma both headed to the Nasdaq this morning as momentum continues to build for biopharma IPOs.
As Priovant works toward approval…
As Priovant works toward approval of potential blockbuster brepocitinib as a treatment for dermatomyositis, the North Carolina biotech has presented promising results for the TYK2/JAK1 inhibitor in another rare skin condition.
Angitia Biopharmaceuticals has…
Angitia Biopharmaceuticals has unveiled its second mega-round in 14 months, revealing a $130 million series D financing that positions the biotech to take three bone disease prospects deeper into the clinic.
Clinical-stage antibody company…
Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build.
Quell Therapeutics is pressing…
Quell Therapeutics is pressing pause on an engineered regulatory T-cell therapy for liver transplant patients in order to focus resources on a preclinical autoimmune candidate.
Bayer has linked asundexian to a…
Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.
Eikon Therapeutics is heading to…
Eikon Therapeutics is heading to the Nasdaq this morning with an upsized $381 million IPO in a further sign of the renewed appeal of the public markets.
As Eli Lilly awaits an FDA…
As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage drugs, including a gene therapy from its $1 billion acquisition of Prevail Therapeutics.
Novartis has nixed six early-stage…
Novartis has nixed six early-stage pipeline programs, swapping in two new phase 1 cancer candidates as replacements.
Stem cell therapy biotech PrimeGen…
Stem cell therapy biotech PrimeGen US is taking the less-traveled SPAC route to the public markets.
Luke Miels had only been at the…
Luke Miels had only been at the helm of GSK for 20 days when he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest.
Novo Nordisk’s CEO was…
Novo Nordisk’s CEO was magnanimous about Pfizer’s victory in last year’s bidding war over an obesity biotech, but the Danish pharma is making no secret of the fact it remains on the lookout for a
Amgen’s bad luck in lupus may…
Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon Therapeutics in 2023, hit the primary endpoint in a phase 2 trial for discoid lupus erythematosus.
National Institutes of Health…
National Institutes of Health Director Jayanta Bhattacharya, M.D., Ph.D., spent much of a Senate committee hearing dancing around direct answers—except when it came to vaccines, a topic on which he finally delivered a clear view